Today: 16 June 2026
Browse Category

NASDAQ:ADAP 19 August 2025 - 16 October 2025

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune Therapeutics shares surged 42% on October 8, 2025, after nearly doubling intraday on September 19, despite no major news and record trading volumes. The company sold its key T-cell therapy programs, including Tecelra, to US WorldMeds for $55 million upfront to pay off debt and avoid insolvency. Q2 net loss reached $30.3 million, with cash reserves at $26 million by mid-year. Analysts remain bearish, with no major buy ratings.
16 October 2025
··
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune shares jumped 52% on October 8, 2025, amid heavy speculative trading, but remain down about 75% year-over-year and trade near $0.20. The company sold its main T-cell therapy programs to US WorldMeds for $55 million upfront, cleared its debt, and now faces “substantial doubt” about its ability to continue. Analysts rate the stock as high risk, with no major firm recommending a Buy.
9 October 2025
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics shares soared 42% to around $0.20 on Oct. 8, 2025, after weeks of extreme volatility and trading volumes topping 705 million shares. The company sold its four main cell therapy programs, including newly approved Tecelra, for $55 million upfront in July to pay off debt and cut its workforce by 62%. Weiss Ratings issued a rare “Sell (E+)” on Oct. 8. No new products have been announced this month.
8 October 2025
·
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····

Stock Market Today

  • SpaceX Shares Rise 6% in Record-Breaking Market Debut
    June 15, 2026, 8:16 PM EDT. SpaceX shares surged 6% early Monday, extending its record-breaking market debut amid strong investor appetite for marquee tech stocks. Despite never turning a profit, SpaceX's revenues have soared, driven by its dominant Starlink satellite broadband service and growing investments in AI infrastructure. Market concerns about a potential bubble persist, with some comparing current valuations to 2000 and 1929 crashes. However, others see the surge as earnings-driven. Notably, lenders remain optimistic, exemplified by Nvidia's $85 billion bond order against a $25 billion offering, signaling robust demand for tech sector debt.

Latest articles

Nasdaq steady in late trading as oil eases, Fed up next

Nasdaq steady in late trading as oil eases, Fed up next

16 June 2026
U.S. stocks soared Monday as falling oil prices and a preliminary U.S.-Iran deal fueled a relief rally, with the Nasdaq up 3.07%, S&P 500 up 1.65%, and Dow closing at a record high; after-hours futures dipped slightly as investors awaited Wednesday’s pivotal Federal Reserve decision and Chair Kevin Warsh’s first post-meeting press conference.
Intel stock gains after BofA upgrade, foundry business in focus

Intel Gains as Chip Shares Recover

16 June 2026
Intel surged to $127.86, topping analyst targets, as chip stocks rallied on easing inflation and AI optimism, but the stock’s gains outpace consensus expectations and recent earnings remain negative; investors now await the unconfirmed July 23 earnings report for proof that demand is driving real revenue growth.
Dave & Buster’s falls after Q1 comes up short, comps slip

Dave & Buster’s falls after Q1 comes up short, comps slip

16 June 2026
Dave & Buster’s shares plunged 4.72% to $12.32, then dropped another 11.2% after hours, after Q1 revenue, adjusted profit, and comparable-store sales all missed expectations; management’s guidance for positive sales trends and free-cash-flow remains the next key catalyst as investors weigh the company’s turnaround credibility.
Go toTop